Atlanta-based HIV/AIDS vaccine developer GeoVax Labs posted a loss of $1.28 million and break-even earnings for the second quarter of 2008. The company says the loss was partially offset by grant revenue from the National Institutes of Health in support of its HIV/AIDS vaccine work.
The company still expects to launch a Phase 2 preventative AIDS vaccine clinical trial this fall.